Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis

Hepatocyte Growth Factor/Scatter Factor (HGF/SF) mediates a wide variety of cellular responses by acting through the Met tyrosine kinase receptor. Inappropriate expression of HGF/SF and/or Met has been found in most types of solid tumors and is often associated with poor prognosis. Importantly, constitutional and sporadic activating mutations in Met have been discovered in human papillary renal carcinomas and other cancers, while autocrine and paracrine signaling of this receptor/ligand pair has been shown to contribute to tumorigenesis and metastasis. Numerous downstream signaling molecules have been implicated in HGF/SF-Met mediated tumorigenesis and metastasis. Stat3 is a downstream signaling molecule activated by HGF/SF-Met signaling, and is reported to contribute to cell transformation induced by a diverse set of oncoproteins. Stat3 is constitutively activated in many primary tumors and tumor cell lines, suggesting that signaling by this molecule may be important for cell transformation. To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3β into the human leiomyosarcoma cell line SK-LMS-1. We found that Stat3β has no effect on the transformed morphology, proliferation, invasion or branching morphogenesis in vitro. By contrast, expression of Stat3β affected HGF/SF-Met mediated anchorage-independent colony formation and prevented tumorigenic growth in athymic nu/nu mice. Thus, Met signaling through Stat3 provides an essential function for tumorigenic growth, which is manifested in vitro by loss of anchorage-independent growth.

[1]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[2]  J. Lammers,et al.  STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.

[3]  P. Comoglio,et al.  Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line , 1988, Journal of cellular biochemistry.

[4]  E. Rosen,et al.  Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epi , 1994, The Journal of clinical investigation.

[5]  P. Comoglio,et al.  Constitutive activation of the RON gene promotes invasive growth but not transformation , 1996, Molecular and cellular biology.

[6]  J. Darnell,et al.  A Single Amino Acid Substitution in the v-Eyk Intracellular Domain Results in Activation of Stat3 and Enhances Cellular Transformation , 1999, Molecular and Cellular Biology.

[7]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[8]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[9]  M. Fiscella,et al.  The mutationally activated Met receptor mediates motility and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Birchmeier,et al.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.

[11]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[12]  J. Downward,et al.  Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway* , 1998, The Journal of Biological Chemistry.

[13]  T. Nakamura,et al.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor , 1992, Molecular and cellular biology.

[14]  H. Kleinman,et al.  Scatter factor induces blood vessel formation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Rosen,et al.  The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase , 2000, Oncogene.

[16]  N. Rahimi,et al.  c-Src Kinase Activity Is Required for Hepatocyte Growth Factor-induced Motility and Anchorage-independent Growth of Mammary Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[17]  C. S. Zong,et al.  Stat3 Plays an Important Role in Oncogenic Ros- and Insulin-like Growth Factor I Receptor-induced Anchorage-independent Growth* , 1998, The Journal of Biological Chemistry.

[18]  Tetsuo Noda,et al.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor , 1995, Nature.

[19]  G. V. Vande Woude,et al.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network , 1996, Molecular and cellular biology.

[20]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[21]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[22]  L. Ferrell,et al.  Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.

[23]  A. Davies,et al.  Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. , 1997, Genes & development.

[24]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[25]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[26]  P. Comoglio,et al.  Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells , 1995, Molecular and cellular biology.

[27]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[28]  S. Rane,et al.  IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled , 2000, Oncogene.

[29]  A. Bardelli,et al.  Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.

[30]  G. V. Vande Woude,et al.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Kaibuchi,et al.  Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. , 2000, Molecular biology of the cell.

[32]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[33]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[34]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[35]  J. Schlessinger,et al.  Activation of the JNK pathway is essential for transformation by the Met oncogene , 1997, The EMBO journal.

[36]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[37]  D. Kamikura,et al.  Pathways Downstream of Shc and Grb2 Are Required for Cell Transformation by the Tpr-Met Oncoprotein* , 1996, The Journal of Biological Chemistry.

[38]  W. Birchmeier,et al.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells , 1993, The Journal of cell biology.

[39]  E. Hudson,et al.  Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.

[40]  J. Turkson,et al.  Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein , 1999, Molecular and Cellular Biology.

[41]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[43]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[44]  Michael Stoker,et al.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.

[45]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[46]  G. V. Vande Woude,et al.  Met expression and sarcoma tumorigenicity. , 1993, Cancer research.

[47]  G. Merlino,et al.  NK1, a Natural Splice Variant of Hepatocyte Growth Factor/Scatter Factor, Is a Partial Agonist In Vivo , 1998, Molecular and Cellular Biology.

[48]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.